human
metapneumoviru
hmpv
lead
caus
acut
respiratori
infect
particularli
children
immunocompromis
patient
elderli
hmpv
close
relat
avian
metapneumoviru
subtyp
c
circul
least
year
nearli
everi
child
infect
hmpv
age
howev
immun
incomplet
reinfect
occur
throughout
adult
life
symptom
similar
respiratori
viral
infect
rang
mild
cough
rhinorrhea
fever
sever
bronchiol
pneumonia
prefer
method
diagnosi
revers
transcriptionpolymeras
chain
reaction
hmpv
difficult
cultur
start
twentyfirst
centuri
seen
discoveri
sever
emerg
new
respiratori
pathogen
caus
human
diseas
includ
sever
acut
respiratori
syndrom
coronaviru
human
metapneumoviru
hmpv
metapneumovirus
envelop
nonseg
negativesens
singlestrand
rna
virus
compris
genu
two
speci
avian
metapneumoviru
hmpv
metapneumovirus
belong
order
mononegaviral
famili
pneumovirida
also
includ
respiratori
syncyti
viru
rsv
avian
metapneumoviru
previous
known
turkey
rhinotrach
viru
discov
turkey
south
africa
sinc
viru
recogn
infect
turkey
chicken
duck
worldwid
signific
econom
impact
viru
low
variabl
mortal
high
morbid
rate
caus
sever
upper
respiratori
infect
well
reproduct
issu
lead
decreas
egg
product
current
four
subtyp
avian
metapneumoviru
base
genet
divers
attach
g
protein
subtyp
first
isol
south
africa
follow
subtyp
b
sever
european
countri
subtyp
c
discov
us
subtyp
identifi
franc
thought
wild
migratori
bird
play
key
role
spread
avian
metapneumoviru
research
netherland
first
identifi
hmpv
store
nasopharyng
sampl
children
respiratori
ill
use
electron
microscopi
random
revers
transcriptionpolymeras
chain
reaction
rtpcr
techniqu
novel
viru
exhibit
cytopath
effect
hemadsorpt
tertiari
monkey
kidney
epitheli
cell
genom
close
relat
avian
metapneumoviru
serotyp
c
homolog
howev
newli
discov
viru
replic
effici
monkey
bird
archiv
sera
contain
neutral
antibodi
hmpv
two
retrospect
canadian
studi
detect
hmpv
specimen
collect
patient
respiratori
ill
us
studi
detect
hmpv
specimen
collect
studi
show
hmpv
circul
undetect
mani
decad
hmpv
negativesens
nonseg
singlestrand
rna
viru
genom
nucleotid
length
compos
eight
gene
encod
nine
protein
nucleoprotein
n
phosphoprotein
p
matrix
protein
fusion
protein
f
protein
small
hydrophob
sh
protein
glycoprotein
g
larg
l
polymeras
protein
tabl
paramyxovirus
n
l
p
protein
form
viral
replic
complex
though
similar
genom
rsv
avian
metapneumoviru
hmpv
possess
gene
order
differ
rsv
lack
nonstructur
protein
hmpv
exhibit
paramyxoviruslik
morpholog
rang
nm
size
envelop
short
protein
spike
project
recent
studi
demonstr
hmpv
infect
led
format
branch
viral
filament
network
intercellular
extens
human
bronchial
epitheli
cell
hmpv
p
protein
coloc
actin
induc
format
intercellular
extens
importantli
hmpv
spread
directli
cell
cell
even
presenc
neutral
antibodi
absenc
attach
factor
heparan
sulfat
direct
viral
spread
mediat
actin
cytoskeleton
replic
hmpv
occur
nasal
lung
tissu
airway
epitheli
cell
primari
target
hmpv
hmpv
thought
attach
target
cell
via
g
protein
interact
heparan
sulfat
glycosaminoglycan
hmpv
f
protein
encod
rgd
argglyasp
motif
engag
rgdbind
integrin
cellular
receptor
mediat
fusion
cell
membran
viral
envelop
phindepend
fashion
like
within
endosom
low
phdepend
fusion
rare
occurr
certain
lineag
f
protein
negativesens
singlestrand
rna
virus
hmpv
negativesens
genom
rna
transcrib
positivesens
mrna
rna
polymeras
translat
translat
viral
glycoprotein
transport
endoplasm
reticulum
golgi
apparatu
plasma
membran
nascent
viral
protein
accumul
polymeras
switch
transcrib
monocistron
mrna
replic
fulllength
positivesens
antigenom
serv
templat
progeni
negativesens
genom
newli
synthes
virion
exit
host
via
bud
plasma
membran
facilit
protein
two
major
genet
lineag
b
divid
sublineag
clade
hmpv
gene
fall
four
clade
suggest
genom
recombin
rare
although
genotyp
b
cocircul
domin
lineag
may
vari
year
year
phylogenet
analys
hmpv
suggest
human
viru
diverg
avian
type
c
year
ago
hmpv
product
infect
bird
thu
hmpv
aris
human
zoonot
infect
viru
adapt
fulli
human
evid
suggest
differ
genet
lineag
metapneumoviru
repres
distinct
serotyp
studi
rodent
nonhuman
primat
show
high
degre
crossneutr
crossprotect
subgroup
hmpv
season
distribut
similar
respiratori
virus
tend
peak
later
month
compar
rsv
influenza
similar
respiratori
pathogen
hmpv
caus
sever
diseas
infant
young
children
elderli
person
underli
chronic
condit
asthma
emphysema
immun
compromis
seroepidemiolog
studi
shown
children
worldwid
infect
hmpv
age
rate
hospit
children
hmpv
infect
highest
first
year
life
occur
throughout
earli
childhood
mani
studi
report
peak
age
hospit
hmpv
month
age
later
peak
age
hospit
rsv
month
cours
year
multipl
subgroup
hmpv
often
circul
subgroup
genet
distinct
vari
across
season
one
lineag
preval
given
season
despit
genet
differ
subgroup
remain
capabl
caus
sever
infect
differ
associ
consist
variat
sever
diseas
hmpv
infect
usual
caus
overt
diseas
viru
rare
detect
asymptomat
children
studi
hospit
outpati
children
worldwid
found
hmpv
associ
acut
respiratori
ill
although
nearli
popul
experi
primari
hmpv
infect
age
hmpv
reinfect
occur
throughout
adult
life
hmpv
identifi
hospit
adult
rochest
new
york
wherea
hmpv
infect
typic
mild
otherwis
healthi
younger
adult
infect
hmpv
lead
increas
diseas
sever
high
morbid
mortal
rate
elderli
retrospect
canadian
studi
show
hmpv
case
patient
least
year
elderli
patient
hospit
subsequ
studi
report
least
hmpv
elderli
patient
infect
outbreak
longterm
care
facil
develop
bronchiti
pneumonia
lead
mortal
preexist
condit
particularli
asthma
play
role
diseas
sever
hospit
hmpv
isol
adult
hospit
acut
asthma
exacerb
like
infect
rsv
infect
hmpv
within
first
two
year
life
risk
factor
later
asthma
one
studi
found
hmpv
patient
asthma
compar
none
rsv
patient
anoth
studi
note
previou
asthma
diagnosi
hmpv
children
age
immunocompromis
patient
underli
medic
condit
sever
affect
hmpv
one
studi
found
mani
hmpv
hospit
patient
age
sever
diseas
cystic
fibrosi
lymphoma
anoth
retrospect
studi
found
immunocompromis
children
hmpv
develop
pneumonia
four
die
respiratori
failur
group
patient
age
year
underli
medic
condit
lymphoma
lung
tumor
coinfect
viral
bacteri
pathogen
may
exacerb
symptom
diseas
viral
coinfect
rate
patient
hmpv
rang
viral
coinfect
seem
impact
diseas
sever
howev
secondari
bacteri
pneumonia
occur
associ
increas
mortal
hmpv
thought
spread
direct
close
contact
infect
individu
object
fomit
symptom
diseas
present
hmpv
similar
respiratori
virus
caus
upper
lower
respiratori
tract
infect
symptom
includ
cough
rhinorrhea
sore
throat
fever
well
lower
respiratori
tract
symptom
wheez
difficulti
breath
hypoxia
clinic
diagnos
commonli
associ
hmpv
bronchiol
pneumonia
although
earli
studi
demonstr
hmpv
replic
caus
diseas
bird
small
anim
model
mice
cotton
rat
hamster
well
nonhuman
primat
semipermiss
sever
studi
show
cotton
rat
permiss
small
anim
model
peak
viru
titer
occur
day
four
post
infect
viral
lung
replic
diseas
vari
differ
inbr
mous
strain
work
publish
balbc
model
exhibit
substanti
diseas
symptom
balbc
mice
may
exhibit
clinic
symptom
difficulti
breath
weight
loss
ruffl
fur
partli
depend
viru
strain
inoculum
histolog
score
reveal
lung
patholog
sever
day
significantli
decreas
day
viral
replic
occur
day
mice
peak
viral
load
day
similar
older
human
age
mice
increas
diseas
sever
higher
viral
titer
diminish
immun
respons
compar
younger
mice
howev
unlik
human
reinfect
occur
throughout
life
immunocompet
mice
product
reinfect
hmpv
note
work
publish
balbc
inbr
strain
base
extens
bodi
rsv
research
investig
focus
model
contrast
cotton
rat
hamster
ferret
infect
hmpv
manifest
observ
clinic
symptom
hamster
ferret
high
viral
replic
respiratori
tract
compar
mice
african
green
monkey
rhesu
macaqu
permiss
hmpv
infect
neither
exhibit
clinic
symptom
hmpv
replic
neutral
antibodi
product
higher
african
green
monkey
compar
rhesu
macaqu
human
anim
mount
neutral
antibodi
respons
hmpv
mice
neutral
antibodi
first
detect
five
seven
day
infect
peak
four
six
week
infect
mous
model
initi
infect
hmpv
protect
reinfect
antibodi
alon
protect
small
anim
model
contrast
macaqu
challeng
week
primari
hmpv
infect
viru
replic
detect
despit
presenc
serum
antibodi
challeng
month
primari
infect
protect
data
suggest
primat
human
antibodi
level
wane
time
facilit
reinfect
prospect
studi
human
note
baselin
hmpv
antibodi
lower
older
adult
subsequ
becam
infect
versu
becom
infect
suggest
protect
effect
antibodi
cytotox
lymphocyt
ctl
contribut
clearanc
hmpv
infect
mice
earli
day
post
infect
infiltr
lymphocyt
monocyt
mononuclear
cell
perivascular
peribronchi
area
lung
increas
number
total
bronchoalveoloar
lavag
cell
start
day
peak
day
return
near
normal
number
day
number
neutrophil
mononuclear
cell
increas
day
day
post
infect
cell
peak
earlier
day
wherea
cell
peak
day
furthermor
deplet
cell
lead
prolong
viral
replic
tcell
epitop
vaccin
alon
reduc
viral
titer
role
natur
killer
nk
cell
unclear
one
studi
deplet
nk
cell
antibodi
report
prolong
viral
replic
wherea
anoth
deplet
nk
cell
specif
antibodi
found
effect
although
cell
play
critic
role
diseas
protect
also
contribut
diseas
sever
caus
hmpv
deplet
either
cell
led
significantli
less
weight
loss
decreas
lung
inflamm
reduc
airway
obstruct
result
collect
show
cell
especi
cell
play
role
enhanc
clinic
diseas
lung
patholog
hmpv
like
respiratori
virus
dampen
immun
respons
infect
specif
mechan
remain
unclear
multipl
studi
demonstr
convincingli
hmpv
interfer
type
interferon
ifn
respons
differ
studi
implic
variou
viral
protein
includ
g
p
sh
suggest
divers
mechan
type
ifn
receptor
ifnar
defici
mice
infect
hmpv
higher
lung
viral
titer
wildtyp
wt
mice
less
lung
inflamm
airway
dysfunct
highlight
import
ifn
pathway
hmpv
clearanc
diseas
hmpv
capabl
infect
human
murin
dendrit
cell
vitro
lead
alter
signal
diminish
cytokin
product
decreas
migrat
reduc
capac
activ
cell
howev
contribut
interact
diseas
protect
vivo
defin
one
way
hmpv
evad
adapt
immun
respons
upregul
program
cell
tcell
surfac
receptor
play
critic
role
downregul
immun
respons
lead
tcell
function
impair
phenomenon
similar
tcell
exhaust
describ
chronic
infect
cancer
infect
hpmv
acut
respiratori
virus
upregul
ligand
lung
splenic
cell
block
ligat
prevent
function
impair
hmpvspecif
cell
lung
mice
lack
greater
percentag
function
hmpvspecif
cell
compar
wt
mice
secondari
hmpv
infect
lung
tcell
effector
function
sever
impair
reinfect
express
high
blockad
ligat
enhanc
tcell
function
result
collect
suggest
pathway
play
import
role
evad
immun
respons
primari
secondari
hmpv
infect
may
contribut
reinfect
standard
method
hmpv
diagnosi
nucleic
acid
amplif
test
sever
commerci
multiplex
molecular
assay
includ
hmpv
avail
viral
cultur
serolog
test
insensit
one
reason
delay
discoveri
hmpv
difficulti
grow
viru
cell
cultur
viru
requir
exogen
trypsin
replic
vitro
capabl
growth
cell
line
produc
robust
cytopath
effect
tertiari
monkey
kidney
rhesu
kidney
cell
furthermor
viral
propag
take
day
longer
treatment
consist
support
care
licens
antivir
hmpv
two
potenti
treatment
investig
ribavirin
immunoglobulin
ribavarin
nucleosid
activ
rna
virus
exhibit
vitro
activ
hmpv
exhibit
efficaci
mice
commerci
intraven
immunoglobulin
ivig
contain
neutral
activ
hmpv
note
antibodi
alon
exhibit
efficaci
prophylact
therapeut
mice
anecdot
report
human
use
ribavirin
ivig
control
trial
guidelin
recommend
use
measur
current
licens
vaccin
hmpv
numer
effort
made
develop
safe
effect
vaccin
earli
crosschalleng
studi
hamster
show
infect
subgroup
produc
immun
respons
protect
subsequ
challeng
subgroup
b
vice
versa
sever
promis
liveattenu
vaccin
coldadapt
liveattenu
hmpv
vaccin
provid
complet
protect
hamster
antibodi
level
increas
immun
cynomolgu
macaqu
immun
provid
complet
protect
viral
replic
challeng
recombin
hmpv
rhmpv
virus
lack
g
sh
protein
exhibit
attenu
immunogen
phenotyp
anim
model
mutat
methyl
transferas
domain
polymeras
integrinbind
rgd
motif
f
protein
attenu
immunogen
protect
cotton
rat
vector
vaccin
approach
effect
anim
model
includ
chimer
rhmpv
contain
avian
metapneumoviru
p
protein
alphavirusvector
hmpv
f
bovin
vector
f
sendai
viru
vector
f
establish
human
challeng
model
success
test
liveattenu
candid
seroposit
adult
provid
platform
futur
clinic
trial
anoth
method
vaccin
heatkil
formalininactiv
viru
major
concern
nonrepl
hmpv
vaccin
experi
formalininactiv
rsv
firsv
vaccin
firsv
induc
aberr
immun
respons
fail
protect
led
enhanc
respiratori
diseas
vaccine
upon
natur
rsv
infect
anim
studi
replic
result
firsv
clinic
trial
similar
firsv
fihmpv
heatinactiv
hmpv
vaccin
mice
cotton
rat
macaqu
led
enhanc
diseas
follow
viral
infect
high
mortal
increas
level
cytokin
lung
inflamm
studi
show
kind
vaccin
induc
protect
immun
may
lead
increas
morbid
mortal
comparison
inactiv
vaccin
subunit
vaccin
contain
partial
fulllength
viral
protein
particularli
hmpv
f
protein
encourag
sever
studi
recombin
f
protein
report
protect
immun
without
enhanc
diseas
cotton
rat
hamster
nonhuman
primat
anoth
nonrepl
vaccin
approach
viruslik
particl
use
hmpv
f
protein
express
human
embryon
kidney
epitheli
cell
gener
use
retrovir
vector
approach
induc
neutral
antibodi
case
function
tcell
respons
lead
protect
without
sign
enhanc
diseas
unfortun
although
subunit
vaccin
induc
immun
respons
challeng
hmpv
immun
respons
may
rapidli
wane
time
may
requir
multipl
immun
ctl
epitop
employ
peptid
vaccin
mice
ctl
epitop
vaccin
protect
mice
hmpv
infect
reduc
viral
load
lung
immunopatholog
gener
effector
memori
tcell
respons
enhanc
helper
type
cytokin
express
reduc
cytokin
express
peptid
vaccin
approach
induc
function
memori
cell
associ
reduc
viral
titer
recent
studi
construct
multiepitop
peptid
mep
consist
six
bcell
epitop
four
ctl
epitop
two
helper
cell
epitop
mep
caus
strong
humor
immun
indic
increas
antibodi
level
cellmedi
immun
indic
increas
lymphocyt
level
activ
although
hmpv
discov
mani
advanc
understand
mechan
hmpv
caus
diseas
serolog
evolutionari
studi
indic
hmpv
circul
mani
year
undetect
robust
anim
model
establish
candid
vaccin
antibodi
develop
howev
still
much
field
regard
pathogenesi
immun
antivir
vaccin
yet
discov
jvw
serv
scientif
advisori
board
quidel
independ
data
monitor
committe
glaxosmithklin
ns
compet
interest
jvw
support
nation
institut
health
grant
ns
support
nation
institut
health
grant
funder
role
studi
design
data
collect
analysi
decis
publish
prepar
manuscript
